In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Roche Holding AG (RHHVF). The company’s shares closed last Tuesday at $352.50.
According to TipRanks.com, Vosser is a 4-star analyst with an average return of 11.0% and a 72.7% success rate. Vosser covers the Healthcare sector, focusing on stocks such as Molecular Partners AG, Sanofi, and UCB SA.
Roche Holding AG has an analyst consensus of Strong Buy, with a price target consensus of $419.25, representing a 20.6% upside. In a report issued on August 18, Morgan Stanley also maintained a Buy rating on the stock with a CHF372.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $399.00 and a one-year low of $271.11. Currently, Roche Holding AG has an average volume of 3,714.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
